Because folates are important in nucleotide synthesis, antifolates like methotrexate are useful chemotherapies. Methotrexate inhibits dihydrofolate reductase (DHRF), preventing the reduction of dihydrofolate as it accumulates in cells synthesizing thymidylate. This depletes cells of the reduced folates needed for thymidylate and purine synthesis, which, in turn, disrupts DNA replication, thus killing dividing cells in tumors and some normal tissues.
Folates and some antifolates possess a single terminal benzoylglutamate and are converted intracellularly from monoglutamates into polyglutamates by an enzyme, folylpolyglutamyl synthetase (FPGS) , that attaches up to six glutamyl groups in ␥-peptide linkage to the terminal benzoylglutamate. Polyglutamylation causes 1) intracellular folate and antifolate accumulation because ionized polyglutamates cross cell membranes ineffectivelyefflux of methotrexate polyglutamates out of cells is 70 times slower than that of the monoglutamate-and 2) enhanced affinity of folates for enzymes utilizing them as cofactors, increased antifolate enzyme inhibition, and inhibition by antifolates of an expanded range of enzymes (1, 2) .
Because methotrexate is polyglutamylated less efficiently than are folates, reductions in FPGS activity that do not alter folate polyglutamylation reduce methotrexate polyglutamylation and efficacy. FPGS mutations render human leukemias antifolate resistant (3) (4) (5) (6) (7) . Human sarcomas are intrinsically methotrexate resistant due to low FPGS activity (8) . The least toxic antifolates have a greater number of total and higher order polyglutamylates in tumors than in normal tissues (9) .
Transfecting mutant cells that lack FPGS activity with an FPGS expression cassette increases their sensitivity to 4-hour methotrexate pulses in culture, a clinically relevant model system (10) . However, the issue of whether tumor cells already expressing FPGS can be imbued with enhanced methotrexate sensitivity after FPGS gene delivery has not been addressed. Methotrexate's toxicity for gastrointestinal mucosa and bone marrow could be alleviated by a gene therapy that enhances the drug's tumor-specific toxicity.
Therefore, we conducted a preliminary evaluation of FPGS gene delivery followed by low-dose antifolate treatment as a cancer gene therapy. Antifolate pulse sensitivity of a glioma cell line transfected with an expression cassette containing the FPGS complementary DNA (cDNA) was evaluated in culture and in subcutaneous tumors grown in immunodeficient nude mice. The bystander effect of transfectants on nontransfectants and its possible mechanism were also studied, as were antifolate pulse sensitivities of cultured glioma cells transduced with a viral vector carrying the FPGS cDNA.
is a hybrid amplicon containing the following: 1) the herpes simplex virus-1 (HSV-1) origin of DNA replication, oriS, and DNA cleavage/packaging signal, pac, which allow the plasmid to replicate and be packaged into HSV-1 virions in cells cotransfected with a cosmid set containing the HSV-1 genome and deleted in pac signals (14) ; 2) the Epstein-Barr virus (EBV) oriP region and the EBNA-1 (Epstein-Barr nuclear antigen-1) cDNA under the control of the Rous sarcoma virus promoter, which allow episomal replication; 3) the green fluorescent protein (gfp) cDNA under the control of the HSV immediateearly 4/5 promoter; and 4) a cloned transgene of interest under the control of the CMV IE 1 promoter.
Tissues and Cell Lines
Human glioblastoma and astrocytoma tissues were obtained from D. Louis (Massachusetts General Hospital); normal human liver tissue and human liver tissue containing colon carcinoma metastases were obtained from K. Tanabe (Massachusetts General Hospital). All cell lines were grown at 37°C in a 5% CO-95% air atmosphere in Dulbecco's modified Eagle medium (DMEM) (Sigma Chemical Co.) containing 10% fetal bovine serum (Sigma Chemical Co.), 100 U/mL penicillin, and 100 g/mL streptomycin (Sigma Chemical Co.). The rat 9L gliosarcoma cell line has been described previously (15) . The cell line 9L/BAG expresses the histochemically detectable marker ␤-galactosidase (LacZ) and was generated by infecting 9L with the BAG retrovirus (16) . The human glioblastoma cell line U87MG (17) was purchased from the American Type Culture Collection (ATCC; Manassas, VA). The human glioblastoma cell line Gli36 was provided by D. Louis. The rat glioma line C6, derived from a nitrosomethylurea-induced brain tumor (18) , was purchased from ATCC. The C6/13 cell line is a clone derived from lipofectamine-mediated transfection of C6 cells with connexin43 and guanine phosphoribosyltransferase (gpt) cDNAs and selecting cells for gpt expression (19) ; these cells were provided by C. C. G. Naus (University of Western Ontario, London, Canada). 9L/CD and 9L/TK (20) cell lines were developed in our laboratory and express Escherichia coli cytosine deaminase (CD) and herpes simplex virus thymidine kinase (HSV-TK), respectively. The J3T canine glioblastoma cell line derives from a spontaneous tumor in a beagle dog and was provided by M. Berens (Barrow Neurological Institute, Phoenix, AZ). The 2-2 cell line was generated by transfecting Vero African green monkey kidney cells with the HSV-1 ICP 27 gene; these cells were provided by Rozanne Sandri-Goldin (University of California, Irvine).
Transfection of 9L, Gli36, U87, C6, and C6/13 cells with pCDNA3.1/FPGS was carried out by use of lipofectamine (Life Technologies, Inc. [GIBCO BRL], Gaithersburg, MD), followed by cloning under selection in medium containing 1 mg/mL G418 (neomycin analogue; Life Technologies, Inc.), thereby generating 9L/FPGS, Gli36/FPGS, U87/ FPGS, C6/FPGS, and C6/13/FPGS cell lines. All clones proliferated at rates comparable to those of the parental cell lines. Connexin43 expression in the C6, C6/FPGS, C6/13, and C6/13/FPGS cell lines was verified by use of immunocytochemistry, as described previously (19) .
Cell Culture Survival Studies
Cells were plated in triplicate at 8 × 10 5 cells per 10-cm-diameter plate or 4 × 10 5 cells per well in six-well plates. For bystander effect studies, the same total number of cells was used, with varying percentages of 9L/FPGS cells mixed with 9L cells. Cells were allowed to adhere for 4 hours, after which the medium was replaced with medium containing methotrexate or edatrexate. After 4 hours of drug exposure, plates were washed three times with phosphate-buffered saline (PBS). Drug-free medium was then added, and 3 days later cells were trypsinized and counted on a model ZM Coulter apparatus. Dose-response curves were generated by use of SigmaPlot 3.0 (SPSS Inc., Chicago, IL), with curvefitting parameters based on the MarquardtLevenberg method (21) used to determine ED 50 (drug concentration that produces 50% survival).
Bystander Effect Studies
The bystander effect was evaluated by calculating transmission efficiency (TE):
The superscripts 0, N, and 100 designate the ED 50 values for cultures containing 0%, N%, and 100% transfected cells. The transmission efficiency indicates how well the drug's effect is transmitted from transfected to nontransfected cells; i.e., a TE of 50% means the nontransfectants in the coculture experience half the concentration of the active drug that transfectants experience.
Conditioned medium was harvested from untreated 9L and 9L/FPGS cells and from 9L and 9L/ FPGS cells that had been pulsed with 900 nM edatrexate for 4 hours followed by 3 days' growth in drug-free medium. Some conditioned medium was dialyzed overnight (Spectra/Por Cellulose Ester Membrane, 1000 molecular weight cutoff) at 4°C. Nondialyzed conditioned medium was left overnight at 4°C to control for product degradation. Conditioned medium (4 mL) (filtered through 0.2-m sterile acrodisc filter) plus 2 mL of fresh medium was added to 10-cm-diameter plates containing 9L/ BAG cells (1000 cells per dish, clonogenic efficiency approximately 20%) plated the previous day. Leucovorin (1 mM) was added to some plates. Six days later, the cells were fixed with 4% paraformaldehyde in PBS. Fixed cells were stained for ␤-galactosidase by incubation overnight in a solution containing 35 mM potassium ferricyanide, 35 mM potassium ferrocyanide, 2 mM magnesium chloride, and 0.2% 5-bromo-4-chloro-3-indolyl-␤-Dgalactoside (Xgal; Fisher Scientific Co., Pittsburgh, PA) at pH 7.3 (23) . The next day, blue colonies greater than 1 mm in diameter were counted.
The time and density dependence of bystander effects were studied by coculturing 80% 9L/BAG cells with 20% 9L/FPGS, 9L/TK, or 9L/CD cells (the latter two used for comparative purposes) in six-well plates so that the total number of cells was 5 × 10 5 (high density-all cells in contact with each other; 51 500 cells/cm 2 ) or 5 × 10 3 (low density-no cell-to-cell contact; 515 cells/cm 2 ). Cells were treated with 900 nM edatrexate (4-hour pulse followed by 3 days' growth in drug-free medium), 9 g/mL (36 M) ganciclovir (3-day continuous exposure; Cytovene; Hoffmann-La Roche Inc., Nutley, NJ), or 90 g/mL (697 M) 5-fluorocytosine (3-day continuous exposure; Sigma Chemical Co.). These concentrations represent the highest concentrations that are relatively nontoxic to 9L or 9L/BAG cells. Every 24 hours for 3 days, triplicate sets of untreated and drug-treated cocultures were fixed and stained for ␤-galactosidase expression, as described above. Blue and white cells were counted under a light microscope (Nikon, Melville, NY). Cultures of 100% 9L, 9L/FPGS, 9L/CD, and 9L/TK cells with identical numbers of cells were treated with the same drug concentrations and counted under a microscope and using a ZM Coulter Counter. Ten fields were counted at 10× (low density) and 40× (high density). With the use of known dimensions of microscope fields and wells, total numbers of LacZpositive and LacZ-negative cells in each well and percent survival were calculated for each drug at each time point for low-and high-density plates.
In another study, a Falcon inert micropore membrane with pore diameter of 0.4 m (Fisher Scientific Co.) was used to generate upper and lower layers of cells in six-well plates that were physically separated but that exchanged media. Cells (5 × 10 5 ) were plated in each chamber and allowed to adhere for 4 hours. Wells contained all possible combinations of 9L and 9L/FPGS. Some cells were treated with 900 nM edatrexate for 4 hours, washed three times in PBS, grown for 3 days in drug-free medium, trypsinized, and counted on a ZM Coulter apparatus.
The role of gap junctions in the bystander effect was investigated by comparing the bystander effect caused by edatrexate pulsing of cocultures containing 20% C6/FPGS plus 80% C6 to that caused by pulsing a coculture containing 20% C6/13/FPGS plus 80% C6/13.
Viral Vector Generation
Helper virus-free stocks of M12Y-FPGS and M12Y amplicon vectors were generated by lipofectamine-mediated cotransfection of 2-2 cells with amplicon DNA and a set of five overlapping cosmids (C6⌬a48⌬a) spanning the HSV-1 genome (24) with deleted pac sequences (14) . Vector was harvested 72 hours after transfection by scraping the cells, repeated freezing and thawing, sonification, and centrifugation at room temperature for 5 minutes at 800g to remove cellular debris. Vector stocks were titered on the 2-2 cell line by counting gfp-positive cells 24 hours after infection by use of a standard fluorescence microscope (#78947 fluorescence illuminator; Nikon). Infection at a multiplicity of infection (MOI) of 1 transducing unit per cell (titered on cells from the 2-2 line) produced 50% gfp-positive J3T and Gli36 cells. After cells transduced at this MOI were allowed to replicate for 3 days in the absence of selection, sensitivities of the transduced cells to the highest edatrexate pulses nontoxic to M12Y-transduced cells (Gli36-1 nM; J3T-5 M) were measured.
Enzyme Assay
FPGS activity was measured by use of a modification of a previously described protocol (25) . Cells were trypsinized, suspended in 25 mM Tris-HCl (pH 7.5), 5 mM 2-mercaptoethanol, 2 g/mL aprotinin (Sigma Chemical Co.), and 1 g/mL leupeptin (Sigma Chemical Co.), and then sonicated (550 Sonic Dismembrator; Fisher Scientific Co.). Sonicated cells were centrifuged at 4°C at 10 000g for 3 minutes to remove cellular debris. Protein concentration was calculated by use of the Bradford assay (Bio-Rad Laboratories, Hercules, CA). After tumor margins were confirmed histologically, frozen tissue was ground into small pieces, suspended in lysis buffer (50 mM Tris [pH 7.4], 250 mM NaCl, 0.1% Nonidet P-40 [NP40], 5 mM EDTA, 2 g/mL aprotinin, and 1 g/mL leupeptin), homogenized (Brinkmann Instruments, Inc., Westbury, NY), and kept on ice for 1 hour to allow for completion of lysis. For the detection of the low FPGS activity in tissue, samples were concentrated by use of an Integrated Speed Vac (Savant Instruments, Inc., Farmingdale, NY), after which protein concentration was determined by use of the Bradford assay. The FPGS enzymatic assay reaction mixture consisted of 1 M Tris (pH 9.75), 50 mM glycine, 100 M aminopterin, 1 mM glutamate, 50 M [ 3 H] glutamate (1 Ci/L; 50 Ci/mmol; Du Pont NEN, Boston, MA), 5 mM adenosine triphosphate, 10 mM MgCl 2 , 20 mM KCl, 100 mM 2-mercaptoethanol, 0.1 g/L BSA, and 0.4-0.8 mg of cellular protein. The reaction was carried out in 500 L at 37°C for 2 hours and was terminated by the addition of 1.5 mL of ice-cold 30 mM 2-mercaptoethanol and 10 mM glutamate. Free glutamate was separated from glutamate bound to aminopterin by chromatography on a 1-1.5-mL bed volume minicolumn (Poly-Prep Chromatography Column; Bio-Rad Laboratories) containing DE52 DEAE cellulose (Whatman Inc., Clifton, NJ). The column was equilibrated with 5 mL of 10 mM Tris (pH 7.5) and 80 mM NaCl. The terminated reaction was then applied to the column. The column was washed with 5 mL of equilibration buffer to remove unincorporated glutamate. Glutamylated aminopterin was then eluted with 3 mL of 0.1 N HCl with the eluant collected in a scintillation vial containing 10 mL of scintillation fluid (ScintiVerse II; Fisher Scientific Co.) and subsequently counted in a scintillation counter.
Thin-Layer Chromatography of Methotrexate Polyglutamates
Cells (10 6 9L or 9L/FPGS) were plated in 6-cmdiameter dishes. After adhering for 4 hours, cells were incubated with 2 M 3Ј, 5Ј,7-[ 3 H] methotrexate (Moravek Biochemicals; Brea, CA). After 24 hours, cells were trypsinized, centrifuged at 4°C for 10 minutes at 2000g, resuspended in 300 L of deionized water, sonicated, and centrifuged at 4°C for 5 minutes at 800g briefly to remove debris. Proteins were precipitated with 1 mL of methanol at −20°C for 2 hours and removed by centrifugation at 4°C at 20 000g for 30 minutes. The supernatant was concentrated to 30 L under a stream of N 2 at 37°C on a Meyer N-Evap Analytical Evaporator (Organomation Associates Inc., Northborough, MA). From each sample, 1 L was used for the Bradford protein assay and for scintillation counting. Counts per minute (cpm) were converted into moles of drug taken up by determining the cpm of a known quantity of [ 3 H] methotrexate. Methotrexate polyglutamates were separated by ascending thin-layer chromatography (TLC) of samples on Baker Si250PA silica gel plates (Fisher Scientific Co.), as described previously (26, 27) . Plates were eluted with a chloroform-methanolacetic acid mixture (2 : 2 : 1) containing 20 mg/mL cetyl trimethylammonium bromide (Sigma Chemical Co. 
In Vivo Experiments
Cells ( institutional guidelines. After 14 days, when the tumors had reached an average volume of 60 mm 3 , the mice were randomly divided into experimental groups with five mice per group. The maximum tolerated dose (MTD) of methotrexate is 50 mg/kg per day for humans, compared with 9 mg/kg per day for nude mice, corresponding to peak plasma levels of 0.1 and 0.03 mM, respectively (28, 29) . Therefore, nude mice were given intraperitoneal injections of 9 mg of methotrexate/kg body weight or 3 mg edatrexate/kg body weight dissolved in 200 L of 0.9% NaCl administered daily (MTD) or every third day. Tumor size was measured weekly by use of calipers. Tumor volume was calculated as length × width × height, as described previously (20) .
Statistical Analysis
All experiments were performed in triplicate, and comparisons of 9L to 9L/FPGS were made by use of Student's t test. Error bars on graphs are 95% confidence intervals and data points were fit to sigmoidal dose-response curves by use of SigmaPlot 3.0. In Table 1 , 95% confidence intervals are given. All P values are two-sided, with statistical significance defined as P<.05. (Fig. 1, C and D Fig. 1, A and B . Differences represent interexperimental error and the fact that the 9L and 9L/FPGS data in Fig. 1, A and B , and in the table were derived from a wider range of concentrations than the data in Fig. 1 , C and D.
RESULTS

Transfecting 9L With FPGS cDNA
Human brain tumor tissues possess 10-fold less FPGS activity than does colon carcinoma (Table 1) , an antifolatesensitive tumor (30) . Initially, 9L cells were transfected with FPGS because they are readily transfectable, used in gene therapy studies (20, 31) , and had the lowest FPGS activity of the glioma cell lines tested (Table 1) . 9L cells and clones selected after transfection with a plasmid containing the FPGS cDNA were treated with 0.3 M methotrexate for 4 hours, followed by 3 days in drug-free medium. One clone, 9L/FPGS, displayed 40% survival after methotrexate pulse treatment compared with 90% survival for 9L.
The FPGS activity of 9L/FPGS cells was more than fourfold greater than that of 9L ( Table 1 ). Evidence that increased FPGS activity enhanced the methotrexate pulse sensitivity of 9L/FPGS came from the similar sensitivity of 9L and 9L/FPGS to pulses of the nonpolyglutamylatable antifolate PT523 (data not shown).
Measuring Methotrexate Polyglutamates in 9L and 9L/FPGS
The FPGS enzyme assay quantifies drug converted into any of five polyglutamates. However, only MTX-Glu 4 
Methotrexate Pulse Dose-Response of 9L and 9L/FPGS
9L and 9L/FPGS cells were treated with 4-hour pulses of varying methotrexate concentrations (Fig. 1, A) . ED 50 values of 2.9 M (9L) and 101 nM (9L/ FPGS) were obtained ( 
In Vivo Methotrexate Treatment of 9L and 9L/FPGS Tumors
The methotrexate sensitivities of subcutaneous 9L and 9L/FPGS tumors in nude mice were compared. Mice bearing 9L or 9L/FPGS tumors were treated with methotrexate daily or every third day. Fold growth relative to when treatment commenced was plotted versus time (Fig.  2, A) . 9L/FPGS tumors responded better 
Other Antifolates
Next, 9L and 9L/FPGS were pulsed with edatrexate, aminopterin, and DMPDDF, drugs with higher FPGS affinity than methotrexate [aminopterin > edatrexate ‫ס‬ DMPDDF > methotrexate (1, 11, 12, 32) ]. The separations between the dose-response curves of 9L and 9L/ FPGS cells pulsed with aminopterin or DMPDDF (not shown) were comparable to those obtained with methotrexate. However, edatrexate dose-response curves (Fig. 1, B) displayed greater separation than methotrexate curves (Fig. 1,   A) . ED 50 values for edatrexate pulses were 1.2 M (9L) and 18 nM (9L/FPGS), a 67-fold difference, approximately twice the methotrexate ED 50 enhancement ( Table 1 ). The cell lines responded differently over a 10 000-fold range of edatrexate concentrations, greater than the 100-fold range seen with methotrexate.
Bystander Effects
Therapeutic effectiveness of a vectorcarried gene at low transduction efficiencies requires bystander effects, enabling transduced cells to confer cytotoxicity on nearby nontransduced cells by transferring toxic metabolites (33, 34) . Doseresponse curves were generated for cultures of 9L cells, 9L/FPGS cells, and a coculture (20% 9L/FPGS plus 80% 9L) of both cells treated with antifolate pulses (Fig. 1, C and D) . Based on the ED 50 values (Table 1) , the TEs in cocultures containing 20% 9L/FPGS were 50% (methotrexate) and 87% (edatrexate). Cocultures containing 10% and 1% 9L/ FPGS were treated with 4-hour edatrexate pulses. The resulting ED 50 values ( Fig. 1,  D ; Table 1 ) gave TEs of 64% (10% 9L/ FPGS) and 33% (1% 9L/FPGS).
Bystander Effect Mechanistic Studies
Separation of transfectants and nontransfectants. Conditioned medium was harvested from 9L or 9L/FPGS cells that had been exposed to edatrexate for 4 hours, washed, and incubated for 3 days in drug-free medium. The clonogenicity of 9L/BAG in this conditioned medium was determined. Because of washes after pulsing, edatrexate in conditioned medium must derive from edatrexate that was retained intracellularly and released after pulsing. 9L/BAG cells exposed to conditioned medium from 9L/FPGS cells pulsed with edatrexate formed 64% as many colonies as those in conditioned medium from non-edatrexate-treated 9L/ FPGS cells. Equal clonogenicity occurred with conditioned medium from edatrexate-treated or non-edatrexate-treated 9L. Conditioned medium from edatrexatetreated 9L cells was less toxic than that from edatrexate-treated 9L/FPGS cells (P<.005). Medium from edatrexatepulsed 9L/FPGS cells was nontoxic until 72 hours of conditioning. Toxicity of the medium was reversed by the addition of leucovorin or by dialysis. Next, 9L and 9L/FPGS cells were cultured in wells in which a membrane prevents cell-to-cell contact but allows exchange of media. 9L cells sharing wells with 9L/FPGS cells displayed 60.9% survival after edatrexate pulsing, a statistically significant reduction (P<.01) compared with the 88.2% survival seen after pulsing 9L cells sharing wells with 9L cells. Thus, at least part of the bystander effect observed after edatrexate pulsing of cocultures results from the release of edatrexate by transfectants, followed by re-uptake by nontransfectants.
Bystander effect density and time dependence. High-and low-density cocultures containing 80% 9L/BAG cells and 20% 9L/CD, 9L/TK, or 9L/FPGS cells were pulsed (edatrexate) or treated continuously (5-fluorocytosine and ganciclovir) for 3 days. Every 24 hours, ␤-galactosidase-positive (9L/BAG) and ␤-galactosidase-negative (drug-sensitive 9L) cells were counted. At high density, pulsing with edatrexate produced 20% (1 day) and 7% (3 days) 9L/FPGS survival, while cocultured 9L/BAG experienced 48% survival after 3 days (Fig. 3) . Similar results were obtained with low-density 9L/ BAG plus 9L/FPGS cocultures (Fig. 3) . The 9L/TK and 9L/CD bystander effects exceeded those of 9L/FPGS (Fig. 3) . Low density abrogated the HSV-TK bystander effect but not the CD and FPGS bystander effects (Fig. 3) . While FPGS bystander cells experienced less toxicity than CD or HSV-TK bystander cells, drug administration killed 9L/FPGS cells more quickly than it did 9L/CD or 9L/TK cells (Fig. 3) . Thus, not only is cell-to-cell contact not required for the FPGS bystander effect but also it does not enhance the effect.
Role of gap junctions. C6 and C6/13 glioma cells (19) were transfected with the FPGS cDNA, generating clones C6/ FPGS and C6/13/FPGS, which displayed enhanced edatrexate pulse sensitivities despite high pre-existing FPGS activities (Table 1) . Cocultures containing 20% FPGS transfectants produced TEs of 80% for C6 and C6/13, suggesting that gap junctions did not enhance the FPGS bystander effect.
Transfecting and transducing human and canine cells with FPGS. Human glioblastoma cell lines Gli36 and U87 were transfected with the FPGS cDNA, generating Gli36/FPGS and U87/ FPGS cell lines. Although Gli36 cells are very sensitive to edatrexate pulses, Gli36/ FPGS was sixfold more sensitive (Table  1) . Edatrexate-pulse sensitivity was also enhanced in U87/FPGS ( 
DISCUSSION
Others have shown that tumoral FPGS mutations cause antifolate resistance (3) (4) (5) (6) and that transfecting mutant cells lacking FPGS activity with FPGS enhances methotrexate pulse susceptibility (10) . This report describes the novel finding that transfecting glioma cell lines already expressing FPGS with a plasmid containing the FPGS cDNA increases antifolate pulse sensitivity in culture. Pulses model clinical antifolate usage, which relies on moderate-to high-level pulse doses at weekly or every-2-week intervals (3, 10) . Transfectants displayed enhanced antifolate sensitivity in vivo. FPGS transfectants exerted a slight bystander effect on nontransfectants after edatrexate pulsing, apparently reflecting edatrexate release by transfectants after the pulse. The bystander effect occurred in vivo and in chemosensitized, cultured glioma cells transduced with a hybrid amplicon encoding FPGS.
The original prodrug-activating enzymes, HSV-TK and CD, were prokaryotic. Interest has developed in mammalian enzymes that activate chemotherapy drugs, such as cytosine arabinoside (Ara-C; cytarabine) phosphorylation by deoxycytidine kinase (dCK) (31) . Ara-C requires enzymatic modification for toxicity, making it a prodrug. However, tumors express dCK normally and are somewhat Ara-C sensitive without gene therapy. Therefore, the chemosensitivity achieved after delivery of genes like dCK tends to be less than that of foreign transgenes like HSV-TK and CD.
Because antifolates are toxic without enzymatic modification, they are not prodrugs. However, FPGS and prodrugactivating enzymes are all "chemosensitizing." In fact, although the 67-fold- enhanced edatrexate sensitivity in 9L/ F P G S i s l e s s t h a n t h e 5 0 0 -f o l d enhancement in 9L/TK, it is near the 80-fold enhancement in 9L/CD (20) 9L/FPGS tumors responded as well to 3 mg of methotrexate/kg per day (not shown) or 9 mg/kg every third day as 9L tumors did to 9 mg/kg per day. The response of FPGS transfectants to lower doses reflects the greater inhibitory effect of antifolate polyglutamates, while the response to lower treatment frequencies reflects polyglutamate retention. Reducing dose frequency may be more beneficial than reducing dose because prolonged drug exposure increases the chance of normal cells entering S phase during drug exposure (1) . The response of 9L/FPGS to treatment every third day supports studies showing that, after a single methotrexate injection, tumors with FPGS activity that is comparable to that measured in 9L/ FPGS cells retain sufficient polyglutamates to occupy all DHFR sites for 48 hours (35) . The lack of tumor regression observed in mice might not occur in humans because of the latter's higher MTD. Although a bystander effect, important because of low transduction efficiencies (38) , seems unlikely with FPGS gene transfer because the strategy enhances intracellular drug retention, earlier studies support the possibility. Intracellular antifolate polyglutamates bind DHFR or are unbound/free in the cytoplasm. The latter can be degraded into monoglutamate by lysosomal ␥-glutamyl hydrolase (2). Once extracellular methotrexate drops after the pulse, intracellular monoglutamylated methotrexate effluxes down its concentration gradient. Decreased intracellular monoglutamylated methotrexate stimulates unbound/free polyglutamate degradation over polyglutamylation. Six hours after methotrexate removal, 43% of methotrexate polyglutamates have left the cell as monoglutamate after cleavage (2) .
Thus, an FPGS bystander effect could arise for the following reasons: 1) if antifolate is retained intracellularly after polyglutamylation by transduced cells; 2) when extracellular drug concentration drops after the pulse, unbound polyglutamates inside surviving transduced cells are cleaved into monoglutamate; 3) if monoglutamate effluxes down its concentration gradient out of transduced cells; and 4) if drug released from transduced cells is taken up by nontransduced cells and given a second opportunity, at a lower concentration, to kill nontransduced tumor cells that survived the pulse. The first two steps have been described (2) , and the last two are supported here. The sensitivity of cells in this study to continuous antifolate exposure suggests that even a small amount of antifolate released after pulsing can be toxic because of its continuous presence. The FPGS bystander effect was less than for other enzymes. Cocultures in which 5% of 9L cells express CD display a TE of 87% (Aghi M, Breakefield XO: unpublished observation). However, the CD bystander effect has produced therapy-related deaths in rodents (39) .
Gliomas were chosen for this preliminary investigation because of their use in cancer gene therapy (20, 31, 33, 40) and because most of these tumors possess relatively low FPGS activity. It is unclear why methotrexate glioma treatment has proven disappointing-hypotheses include the following: that a low replicating fraction confers resistance to S-phasespecific drugs; that methotrexate penetrates spheroid tumors poorly; and distinct glioma enzyme (e.g., FPGS) expression (41, 42) . The hydrophilicity of methotrexate does not entirely prevent blood-brain barrier penetration, since high-dose methotrexate treats central nervous system lymphoma (43) . The bloodbrain barrier near gliomas is usually disrupted or can be disrupted chemically (44) (45) (46) . If the low replicating fraction in gliomas confers methotrexate resistance, increasing tumoral FPGS activity might allow nonreplicating cells to retain drug until they resume replication. If low FPGS activity in gliomas causes methotrexate resistance, FPGS gene transfer can address this limitation.
FPGS gene transfer could be applied to other cancers investigated in gene therapy trials (40) . Some are methotrexate sensitive, and FPGS gene therapy could enhance methotrexate efficacy; others are like gliomas in that methotrexate is not standard therapy but could become an option after FPGS gene delivery.
This report describes the novel finding that FPGS gene transfer into several glioma cell lines enhances antifolate sensitivity and creates a bystander effect in culture and in vivo. The magnitudes of the chemosensitivity enhancement and the bystander effect were close to those of prodrug-activating enzymes. Given the advantages of a nonimmunogenic enzyme-enhancing sensitivity to already moderately effective anticancer agents, FPGS gene transfer merits further investigation.
